Secondary efficacy subanalysis by histology from the phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL).
Ian Flinn
Research Funding - Teva
Richard H. C. Van Der Jagt
Consultant or Advisory Role - Lundbeck; Teva
Honoraria - Celgene; Novartis; Roche
Research Funding - Celgene; Cell Therapeutics; Lundbeck; Roche; Teva
Brad S. Kahl
Consultant or Advisory Role - Genentech; Teva
Research Funding - Genentech
Peter Wood
No relevant relationships to disclose
Tim E. Hawkins
No relevant relationships to disclose
David MacDonald
Consultant or Advisory Role - Lundbeck; Roche
Mark Hertzberg
No relevant relationships to disclose
Yiu-Lam Kwan
No relevant relationships to disclose
David Simpson
No relevant relationships to disclose
Michael Craig
No relevant relationships to disclose
Kathryn S. Kolibaba
Research Funding - Pharmacyclics
Samar Issa
No relevant relationships to disclose
Regina Clementi
Employment or Leadership Position - Teva
Stock Ownership - Teva
Doreen M. Hallman
Employment or Leadership Position - Teva
Mihaela C. Munteanu
Employment or Leadership Position - Teva
Stock Ownership - Teva
Ling Chen
Employment or Leadership Position - Teva
Stock Ownership - Teva
John M. Burke
Consultant or Advisory Role - Alexion Pharmaceuticals; Dendreon; Genomic Health; Seattle Genetics; Spectrum Pharmaceuticals